Effects of allogeneic ALAK cells on reconstitution of B6 recipients with donor-derived cells in spleen
Treatment* . | ALAK/BMC ratio . | No. mice . | Cellularity, × 106 . | Donor chimerism, %† . |
|---|---|---|---|---|
| No ALAK | 0 | 5 | 80.6 ± 16.7 | 79.5 ± 5.2 |
| B10 ALAK | 1:1 | 5 | 82.0 ± 15.1 | 80.9 ± 3.5 |
| B10.D2 ALAK | 1:1 | 6 | 86.2 ± 11.9 | 77.3 ± 5.6 |
Treatment* . | ALAK/BMC ratio . | No. mice . | Cellularity, × 106 . | Donor chimerism, %† . |
|---|---|---|---|---|
| No ALAK | 0 | 5 | 80.6 ± 16.7 | 79.5 ± 5.2 |
| B10 ALAK | 1:1 | 5 | 82.0 ± 15.1 | 80.9 ± 3.5 |
| B10.D2 ALAK | 1:1 | 6 | 86.2 ± 11.9 | 77.3 ± 5.6 |
Values represent mean ± SD.
BMCs from B6-Ly5.2 donors were cultured alone or in the presence of H2-matched or allogeneic ALAK cells for 24 hours before injection into irradiated (8.5 Gy) B6 recipients.
At day 60 after BMT, splenocytes from mice were double stained with FITC-antimouse CD45.2 (Ly5.1, host) and PE-anti-CD45.1 (Ly5.2, donor) mAb and were analyzed on FACScan. Percentages of CD45.1+ cells were obtained by gating on live cells.